The European Commission Signs Deal for 405 Billion Doses of Potential German COVID Vaccine
VOA News
The European
Commission, the European Union's administrative branch, announced Monday a deal
with to purchase 405 billion doses of a potential coronavirus vaccine from
German bio-tech company CureVac.
The announcement comes just
days after EU officials announced a similar deal with German company BioNTech
and U.S. pharmaceutical giant Pfizer for an initial 300 million doses of the
vaccine candidate they jointly produced, which, they say, has proven 90 percent
effective against COVID-19 in late-stage testing.
European Commission President
Ursula von der Leyen told reporters the deal with CureVac is, of course,
conditional on their vaccine proving to be safe and effective.
Von der Leyen said the fifth
CureVac is fifth company the alliance has contracted with a for its COVID-19 vaccine
portfolio.
She said they are already
working on a deal with U.S. pharmaceutical company Moderna, for a sixth
contract. On Monday, Moderna announced testing showed its vaccine candidate to
also be better than 90 percent effective.
Von der Leyen said the
European Commission hopes to have finalize their contract with Moderna soon.
She said all the vaccines must independently tested by the European Medicines
Agency (EMA) before they will be accepted. She said, "We do not know at
this stage which vaccine will end up being safe and effective... And this is
why we need to have a broad portfolio of vaccines based on very different
technologies."
European nations continue to
see a surge in COVID-19 cases, and many have implemented at least partial
nationwide lockdowns until the end of the month.
Post a Comment